Assignee
RESPIVERT LTD
GB·52 granted patents·12 pending applications·303 citations·filing 2012–2023
Top patents by PatentIndex Score
64 records- 0197US9624196B2Inhibitor of p38 MAP kinaseRESPIVERT LTD·Filed 2016·Granted Apr 18, 2017·15 cites·5 claims
- 0297US9108950B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2012·Granted Aug 18, 2015·38 cites·13 claims
- 0397US8927563B2Kinase inhibitorRESPIVERT LTD·Filed 2014·Granted Jan 6, 2015·39 cites·6 claims
- 0496US9499486B2Kinase inhibitorRESPIVERT LTD·Filed 2015·Granted Nov 22, 2016·14 cites·10 claims
- 0596US9447076B2Inhibitor of p38 map kinaseRESPIVERT LTD·Filed 2015·Granted Sep 20, 2016·16 cites·18 claims
- 0694US8975285B2P38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2013·Granted Mar 10, 2015·26 cites·3 claims
- 0793US9481648B2Kinase inhibitorsRESPIVERT LTD·Filed 2014·Granted Nov 1, 2016·22 cites·24 claims
- 0892US10738032B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitorsRESPIVERT LTD·Filed 2019·Granted Aug 11, 2020·3 cites·24 claims
- 0992US9475796B21-pyrazolyl-3-((4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2012·Granted Oct 25, 2016·12 cites·14 claims
- 1092US9249125B2Pyrazole derivatives as p38 MAP inhibitorsRESPIVERT LTD·Filed 2013·Granted Feb 2, 2016·30 cites·12 claims
- 1191US10266519B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitorsRESPIVERT LTD·Filed 2017·Granted Apr 23, 2019·6 cites·11 claims
- 1290US10125100B2Kinase inhibitorsRESPIVERT LTD·Filed 2017·Granted Nov 13, 2018·6 cites·4 claims
- 1389US9751837B2Kinase inhibitorsRESPIVERT LTD·Filed 2015·Granted Sep 5, 2017·6 cites·25 claims
- 1489US9724347B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitorsRESPIVERT LTD·Filed 2016·Granted Aug 8, 2017·5 cites·17 claims
- 1588US9850231B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitorsRESPIVERT LTD·Filed 2015·Granted Dec 26, 2017·5 cites·8 claims
- 1687US11208381B2Indole derivatives and their use as protein kinase inhibitorsRESPIVERT LTD·Filed 2020·Granted Dec 28, 2021·2 cites·18 claims
- 1787US9822076B2Kinase inhibitorRESPIVERT LTD·Filed 2016·Granted Nov 21, 2017·3 cites·3 claims
- 1887US9227977B2Phosphoinositide 3-kinase inhibitorsRESPIVERT LTD·Filed 2014·Granted Jan 5, 2016·4 cites·7 claims
- 1986US10238658B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2018·Granted Mar 26, 2019·3 cites·19 claims
- 2085US9790174B2Kinase inhibitorsRESPIVERT LTD·Filed 2016·Granted Oct 17, 2017·3 cites·2 claims
- 2185US9242960B2P38MAP kinase inhibitorsRESPIVERT LTD·Filed 2014·Granted Jan 26, 2016·6 cites·6 claims
- 2283US10669235B2Indole derivatives and their use as protein kinase inhibitorsRESPIVERT LTD·Filed 2017·Granted Jun 2, 2020·2 cites·13 claims
- 2383US10294216B2Pyrazolyl ureas as kinase inhibitorsRESPIVERT LTD·Filed 2017·Granted May 21, 2019·1 cites·13 claims
- 2483US9993478B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitorsRESPIVERT LTD·Filed 2017·Granted Jun 12, 2018·2 cites·19 claims
- 2583US9890185B2Urea derivatives useful as kinase inhibitorsRESPIVERT LTD·Filed 2014·Granted Feb 13, 2018·8 cites·18 claims
- 2683US9796742B2Kinase inhibitorsRESPIVERT LTD·Filed 2016·Granted Oct 24, 2017·2 cites·23 claims
- 2783US9771353B2Kinase inhibitors based upon N-alkyl pyrazolesRESPIVERT LTD·Filed 2014·Granted Sep 26, 2017·3 cites·19 claims
- 2883US9701670B2Pyrazolyl-ureas as kinase inhibitorsRESPIVERT LTD·Filed 2013·Granted Jul 11, 2017·10 cites·18 claims
- 2982US10072034B2Kinase inhibitorsRESPIVERT LTD·Filed 2017·Granted Sep 11, 2018·3 cites·23 claims
- 3080US2024343711A11-pyrazolyl-3- (4- ((2 -anilinopyrimidin- 4 - yl) oxy) napththalen- i - yl) ureas as p38 mapkinase inhibitorsRESPIVERT LTD·Filed 2023·Application pending·0 cites
- 3178US9321773B2CompoundsRESPIVERT LTD·Filed 2014·Granted Apr 26, 2016·2 cites·1 claims
- 3276US11634406B2Inhibitor of p38 MAP kinaseRESPIVERT LTD·Filed 2020·Granted Apr 25, 2023·0 cites·10 claims
- 3376US11142515B2Pyrazolyl-ureas as kinase inhibitorsRESPIVERT LTD·Filed 2019·Granted Oct 12, 2021·0 cites·9 claims
- 3476US9884845B2Pyrazolyl-ureas as kinase inhibitorsRESPIVERT LTD·Filed 2015·Granted Feb 6, 2018·1 cites·17 claims
- 3574US9834560B2CompoundsRESPIVERT LTD·Filed 2016·Granted Dec 5, 2017·1 cites·21 claims
- 3673US9340545B2Quinazolin-4 (3H)—one derivatives used as P13 kinase inhibitorsRESPIVERT LTD·Filed 2013·Granted May 17, 2016·1 cites·8 claims
- 3772US9771354B2Pyrazole p38 map kinase inhibitorsRESPIVERT LTD·Filed 2016·Granted Sep 26, 2017·1 cites·31 claims
- 3870US10815217B2Inhibitor of p38 MAP kinaseRESPIVERT LTD·Filed 2018·Granted Oct 27, 2020·0 cites·13 claims
- 3970US10358445B2Respiratory formulations and compounds for use thereinRESPIVERT LTD·Filed 2014·Granted Jul 23, 2019·1 cites·3 claims
- 4069US10813932B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitorsRESPIVERT LTD·Filed 2019·Granted Oct 27, 2020·0 cites·18 claims
- 4168US10045980B2Inhibitor of p38 map kinaseRESPIVERT LTD·Filed 2017·Granted Aug 14, 2018·0 cites·13 claims
- 4266US9642799B2Crystalline 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-0X0-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamideRESPIVERT LTD·Filed 2013·Granted May 9, 2017·1 cites·18 claims
- 4361US2018000830A1Inhibitors of hemopoietic cell kinase (p-59-hck) and their use in the treatment of influenza infectionRESPIVERT LTD·Filed 2017·Application pending·0 cites
- 4460US9556184B2Phosphoinositide 3-kinase inhibitorsRESPIVERT LTD·Filed 2015·Granted Jan 31, 2017·0 cites·3 claims
- 4559US2018118754A1CompoundsRESPIVERT LTD·Filed 2017·Application pending·0 cites
- 4658US10028959B2Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitorsRESPIVERT LTD·Filed 2017·Granted Jul 24, 2018·0 cites·5 claims
- 4758US9745306B22-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin-4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitorsRESPIVERT LTD·Filed 2014·Granted Aug 29, 2017·0 cites·15 claims
- 4858US2016016934A1Kinase inhibitorsRESPIVERT LTD·Filed 2014·Application pending·0 cites
- 4957US2016045512A1Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza InfectionRESPIVERT LTD·Filed 2015·Application pending·0 cites
- 5056US2015210722A1Kinase inhibitorsRESPIVERT LTD·Filed 2013·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →